← Back to Search

PD-1 Inhibitor

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Phase 2
Waitlist Available
Led By Christine H Chung, MD
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test how well a new immunotherapy drug works in people with skin cancer that has spread and can't be removed by surgery.

Eligible Conditions
  • Skin Cancer
  • Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Response Rate
Secondary study objectives
Overall Survival
Progression Free Survival

Side effects data

From 2023 Phase 3 trial • 608 Patients • NCT03257267
25%
Pyrexia
13%
Diarrhoea
13%
Constipation
13%
Infusion related reaction
13%
Vomiting
13%
Nausea
13%
Subcutaneous abscess
13%
Hyperthyroidism
100%
80%
60%
40%
20%
0%
Study treatment Arm
Chemotherapy to Cemiplimab*
Cemiplimab
Chemotherapy*

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cemiplimab-rwlc treatmentExperimental Treatment1 Intervention
Immunocompromised patients will be given Cemiplimab-rwlc every 3 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cemiplimab-Rwlc
2019
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
567 Previous Clinical Trials
144,916 Total Patients Enrolled
Regeneron PharmaceuticalsIndustry Sponsor
671 Previous Clinical Trials
385,821 Total Patients Enrolled
Christine H Chung, MDPrincipal InvestigatorMoffitt Cancer Center
~1 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top